Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.51 |
| ▸ | SMO | Q99835 | 3/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2825721 | 0.94 | HRH3 (0.55) | HRH3DPP4DPP8DPP9GPR119 | |
| SCHEMBL19748857 | 0.93 | HRH3 (0.54) | HRH3DPP4DPP8DPP9GPR119 | |
| SCHEMBL14349592 | 0.85 | EGLN2 (0.53) | HRH3DPP4DPP8DPP9GPR119 | |
| SCHEMBL3452836 | 0.84 | DPP4 (0.53) | HRH3DPP4DPP8DPP9GPR119 | |
| SCHEMBL5089958 | 0.83 | DPP4 (0.52) | HRH3DPP4DPP8DPP9GPR119 | |
| SCHEMBL5210864 | 0.82 | HRH3 (0.51) | HRH3DPP4DPP8DPP9GPR119 | |
| Hydrochloric Acid SCHEMBL5216240 | 0.81 | HRH3 (0.50) | HRH3DPP4DPP8DPP9GPR119 | |
| SCHEMBL13683677 | 0.80 | IRAK4 (0.54) | HRH3DPP4DPP8DPP9PANK3 | |
| SCHEMBL3857428 | 0.80 | IRAK4 (0.54) | HRH3DPP4DPP8DPP9PANK3 | |
| SCHEMBL3048925 | 0.80 | KDM4E (0.54) | GPR119PANK3SMOKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | HRH3 3405/4885DPP4 2653/4885DPP8 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.